Literature DB >> 27746617

Clinical Significance of Quantitative HBsAg Titres and its Correlation With HBV DNA Levels in the Natural History of Hepatitis B Virus Infection.

Vijay K Karra1, Soumya J Chowdhury1, Rajesh Ruttala1, Sunil K Polipalli1, Premashis Kar1.   

Abstract

BACKGROUND/
OBJECTIVE: Quantification of serum hepatitis B antigen (HBsAg) is an important test that marks active infection with hepatitis B and helps in the prediction of the clinical outcome and management of hepatitis B virus (HBV) infection. Correlation with HBV DNA quantitative levels may help in developing strategies for antiviral treatment. This study is aimed to evaluate HBsAg titres in various phase of HBV infection in HBsAg positive patients, and its correlation with HBV DNA viral load levels.
METHODS: 976 HBV related patients were analysed in this retrospective cross-sectional study. Patients were categorised on the basis of the phase of HBV infection: immune tolerant phase (IT, n = 123), immune clearance phase (IC, n = 192), low-replicative phase (LR, n = 476), and HBeAg-negative hepatitis (ENH, n = 185). HBsAg titres were quantified and correlated with HBV-DNA levels and clinical parameters.
RESULTS: Median HBsAg titres were different between each phases of HBV infection (P < 0.001): (4.62 log10 IU/ml), IC (3.88 log10 IU/ml), LR (2.76 log10 IU/ml) and ENH (2.94 log10 IU/ml). HBsAg and HBV DNA levels showed significant correlation in the whole group (r = 0.694, P < 0.001), and this was also observed in different phases of HBV infection. Strong correlation in IT phase (r = 0.603, P < 0.001) and IC phase (r = 0.523, P < 0.001), moderate in LR phase (r = 0.362, P < 0.001) and weak in ENH (r = 0.110, P = 0.04). No correlation was observed between serum HBsAg levels and biochemical parameters.
CONCLUSION: The study demonstrated significant difference in the median baseline values of serum HBsAg titres in different phases of HBV infection and provides additional information in understanding the natural history of HBV-infection.

Entities:  

Keywords:  HBV DNA quantitative; HBV, hepatitis B virus; HBeAg; HBeAg, hepatitis B early antigen; HBsAg; IC, immune clearance phase; IT, immune tolerance phase; LR, low-replicative phase; hepatitis B virus; quantitative HBsAg

Year:  2016        PMID: 27746617      PMCID: PMC5052401          DOI: 10.1016/j.jceh.2016.07.002

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  25 in total

Review 1.  Hepatitis B e antigen-negative chronic hepatitis B.

Authors:  S J Hadziyannis; D Vassilopoulos
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

2.  Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay.

Authors:  Matsuo Deguchi; Naoko Yamashita; Masanori Kagita; Seishi Asari; Yoshinori Iwatani; Takahiko Tsuchida; Kazushige Iinuma; Isa K Mushahwar
Journal:  J Virol Methods       Date:  2004-02       Impact factor: 2.014

3.  Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia.

Authors:  Tin Nguyen; Alexander J V Thompson; Scott Bowden; Catherine Croagh; Sally Bell; Paul V Desmond; Miriam Levy; Stephen A Locarnini
Journal:  J Hepatol       Date:  2010-02-16       Impact factor: 25.083

4.  The change of the quantitative HBsAg level during the natural course of chronic hepatitis B.

Authors:  Yu J Kim; Hyun C Cho; Moon S Choi; Joon H Lee; Kwang C Koh; Byung C Yoo; Seung W Paik
Journal:  Liver Int       Date:  2011-03-22       Impact factor: 5.828

5.  Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.

Authors:  Jerzy Jaroszewicz; Beatriz Calle Serrano; Karsten Wursthorn; Katja Deterding; Jerome Schlue; Regina Raupach; Robert Flisiak; C-Thomas Bock; Michael P Manns; Heiner Wedemeyer; Markus Cornberg
Journal:  J Hepatol       Date:  2010-02-13       Impact factor: 25.083

Review 6.  Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.

Authors:  Henry Lik-Yuen Chan; Alex Thompson; Michelle Martinot-Peignoux; Teerha Piratvisuth; Markus Cornberg; Maurizia Rossana Brunetto; Hans L Tillmann; Jia-Horng Kao; Ji-Dong Jia; Heiner Wedemeyer; Stephen Locarnini; Harry L A Janssen; Patrick Marcellin
Journal:  J Hepatol       Date:  2011-06-28       Impact factor: 25.083

7.  Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers.

Authors:  Chien-Hung Chen; Chuan-Mo Lee; Jing-Houng Wang; Hung-Da Tung; Chao-Hung Hung; Sheng-Nan Lu
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-11       Impact factor: 2.566

8.  The natural history of chronic hepatitis B virus infection.

Authors:  Brian J McMahon
Journal:  Semin Liver Dis       Date:  2004       Impact factor: 6.115

9.  Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

Authors:  Lin-Yan Zeng; Jiang-Shan Lian; Jian-Yang Chen; Hong-Yu Jia; Yi-Min Zhang; Dai-Rong Xiang; Liang Yu; Jian-Hua Hu; Ying-Feng Lu; Lin Zheng; Lan-Juan Li; Yi-Da Yang
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

10.  Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.

Authors:  Rami Moucari; Vincent Mackiewicz; Olivier Lada; Marie-Pierre Ripault; Corinne Castelnau; Michelle Martinot-Peignoux; Agnes Dauvergne; Tarik Asselah; Nathalie Boyer; Pierre Bedossa; Dominique Valla; Michel Vidaud; Marie-Hélène Nicolas-Chanoine; Patrick Marcellin
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

View more
  7 in total

1.  RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.

Authors:  Christine I Wooddell; Man-Fung Yuen; Henry Lik-Yuen Chan; Robert G Gish; Stephen A Locarnini; Deborah Chavez; Carlo Ferrari; Bruce D Given; James Hamilton; Steven B Kanner; Ching-Lung Lai; Johnson Y N Lau; Thomas Schluep; Zhao Xu; Robert E Lanford; David L Lewis
Journal:  Sci Transl Med       Date:  2017-09-27       Impact factor: 17.956

2.  Clinical features of chronic hepatitis B patients with low hepatitis B surface antigen levels and determinants of hepatitis B surface antigen seroclearance.

Authors:  Hideaki Taniguchi; Yoshiaki Iwasaki; Masahito Aimi; Gaku Shimazaki; Akio Moriya
Journal:  JGH Open       Date:  2020-03-12

3.  High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance.

Authors:  Vincenzo Malagnino; Romina Salpini; Gaetano Maffongelli; Arianna Battisti; Lavinia Fabeni; Lorenzo Piermatteo; Luna Colagrossi; Vanessa Fini; Alessandra Ricciardi; Cesare Sarrecchia; Carlo Federico Perno; Massimo Andreoni; Valentina Svicher; Loredana Sarmati
Journal:  PLoS One       Date:  2018-03-29       Impact factor: 3.240

4.  Clinical Characteristics and Correlation Analysis of Subjects with Chronic Hepatitis B Virus (HBV) Infection and Sustained Low Levels of Hepatitis B Surface Antigen (HBsAg).

Authors:  Jun Cheng; Yuzhu Dai; Li Yan; Huajun Zhou; Xujian Xu; Changgui Sun; Zhongyong Wang
Journal:  Med Sci Monit       Date:  2018-03-29

5.  Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg.

Authors:  Tong Wang; Yuzhu Dai; Meng Zhang; Dawei Cui; Xujian Xu; Changgui Sun; Jun Cheng
Journal:  Int J Mol Med       Date:  2018-08-17       Impact factor: 4.101

6.  Clinical characteristics and association analysis of persistent low-level HBsAg expression in a physical examination population with HBV infection.

Authors:  Yuzhu Dai; Feihu Che; Xiaoxiao Jiang; Dawei Cui; Huajun Zhou; Xujian Xu; Changgui Sun; Jun Cheng
Journal:  Exp Ther Med       Date:  2019-11-19       Impact factor: 2.447

7.  Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients.

Authors:  Han Ah Lee; Hyun Woong Lee; Younhee Park; Hyon-Suk Kim; Yeon Seok Seo
Journal:  J Clin Med       Date:  2022-03-21       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.